High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors-Reference-Cited by-同舟云学术

High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors

Published:2019-09-30 Issue:3 Volume:27 Page:933-942
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Nakazawa Nobuhiro,Yokobori Takehiko,Kaira Kyoichi,Turtoi Andrei,Baatar Seded,Gombodorj Navchaa,Handa Tadashi,Tsukagoshi Mariko,Ubukata Yasunari,Kimura Akiharu,Kogure Norimichi,Ogata Kyoichi,Maeno Toshitaka,Sohda Makoto,Yajima Toshiki,Shimizu Kimihiro,Mogi Akira,Kuwano Hiroyuki,Saeki Hiroshi,Shirabe Ken

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1245/s10434-019-07878-8.pdf

Reference49 articles.

1. Youlden DR, Cramb SM, Baade PD. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol. 2008;3(8):819–31.

2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics 2008. CA Cancer J Clin. 2008;58(2):71–96.

3. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 2006;27(4):195–201.